NEXGEL, INC. Asset Impairment Charges
NEXGEL, INC. (NXGL) reported Asset Impairment Charges of $0 for the 12-month period ending 2022-12-31, per its 10-Q filed 2023-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2023-11-13
- NEXGEL, INC. asset impairment charges for fiscal 2021 was $0.00.
| Period end | Asset Impairment Charges 12 month |
|---|---|
| 2022-12-31 | $0.00 10-Q · filed 2023-11-13 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |